BNP Paribas Knock-Out GNMSF/ DE000PH1MW62 /
2024-05-30 2:20:55 PM | Chg.-0.050 | Bid2:28:46 PM | Ask2:28:46 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
2.600EUR | -1.89% | 2.560 Bid Size: 13,000 |
2.590 Ask Size: 13,000 |
Genmab A/S | 1,724.4167 - | 2078-12-31 | Call |
GlobeNewswire
04-30
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...
GlobeNewswire
04-03
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
GlobeNewswire
2023-10-17
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023
GlobeNewswire
2023-09-25
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or...
GlobeNewswire
2023-09-04
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improve...
GlobeNewswire
2021-10-19
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
GlobeNewswire
2021-09-20
Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previous...
GlobeNewswire
2021-07-21
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2021